GlassScriptPhysician profile
Veena V Kumar
NPI 1154883718
$1,002.91
in general payments reported to CMS, 2019-2025
14 companies · $69.47 in 2025
The $69.47 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.74 · 2020: $15.61 · 2021: $55.57 · 2022: $261 · 2023: $388 · 2024: $201 · 2025: $69.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $194.49 | 2023-2024 | Epidiolex |
| Emd Serono, INC. | $149.90 | 2022-2023 | Mavenclad |
| Averitas Pharma INC. | $93.65 | 2023 | Qutenza |
| Ucb, INC. | $93.40 | 2023 | Briviact, Fintepla |
| Genzyme Corporation | $79.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.98 | 2023-2024 | Hyqvia |
| Abbvie INC. | $53.67 | 2025 | |
| Neurelis, INC. | $43.11 | 2024 | Valtoco |
| Genentech USA, INC. | $42.61 | 2022 | |
| Alexion Pharmaceuticals, INC. | $36.31 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $27.74 | 2022-2024 | Andexxa |
| Biogen, INC. | $17.37 | 2022 | |
| Lilly USA, LLC | $15.80 | 2025 | Zepbound |
| Biohaven Pharmaceutical Holding Company LTD. | $14.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veena Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.